Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001993145 | SCV002231701 | pathogenic | Spastic paraplegia | 2021-02-08 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals with SACS-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Tyr1942Metfs*9) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 2638 amino acid(s) of the SACS protein. For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the SACS protein. Other variant(s) that disrupt this region (p.Glu4510Argfs*4) have been determined to be pathogenic (PMID: 29915382, Invitae). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. |
Revvity Omics, |
RCV003136367 | SCV003827337 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2022-05-31 | criteria provided, single submitter | clinical testing |